WS #10944

20:45→21:11 UTC

From 500 msgs · 3 key-dev

BridgeBio announces publication of positive Phase 3 PROPEL 3 trial results for infigratinib in achondroplasia in NEJM, with NDA submission planned for Q3 2026.

BridgeBio Positive Phase 3 Results

BridgeBio announces publication of positive Phase 3 PROPEL 3 trial results for infigratinib in achondroplasia in NEJM, with NDA submission planned for Q3 2026.

Full world state #10944 →